Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

We recently published a list of Did Jim Cramer Nail All These 9 Stock Predictions?w. In this article, we are going to take a ...

US Stock Market Live | Dow Jones | Nasdaq Today | Global markets surged after Trump ruled out firing Fed Chair Powell and ...

Capital International Ltd. CA boosted its Regeneron Pharmaceuticals holdings by 14.5% in Q4, now holding nearly $29.2 million ...

Dimensional Fund Advisors LP boosted its stake in Regeneron Pharmaceuticals by 3% in Q4, totaling over $418 million in ...

Roche posted a Q1 revenue beat, with strong contributions from Phesgo, Xolair, and Polivy, despite larger products lagging.

With Q4 behind us, let’s have a look at Exact ... we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. Quarterly earnings results are a good ...

As April gives way to May, the market braces for a blockbuster week packed with earnings from some of the biggest names ...

Regeneron Pharmaceuticals has received a total of 10 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $797.9, the consensus suggests a potential 32.4% ...

Regeneron Pharmaceuticals has announced that the European Commission has granted conditional marketing approval for Lynozyfic (linvoseltamab) to treat adults with relapsed and refractory multiple ...

Regeneron Pharmaceuticals has a 52-week low of $525.99 and a 52-week high of $1,211.20. The firm has a market capitalization of $65.57 billion, a PE ratio of 15.67, a price-to-earnings-growth ...

Regeneron Pharmaceuticals has a one year low of $525.99 and a one year high of $1,211.20. The firm has a market cap of $65.88 billion, a PE ratio of 15.74, a price-to-earnings-growth ratio of 2.34 ...